Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

MYCN amplification occurs in approximately 20–30% of neuroblastoma patients and correlates with poor prognosis. The TH-MYCN transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the oncogenic function of MYCN. In this study, we identified mit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Lei, Balachandran, Anushree, Larkin, Rebecca, Seneviratne, Janith A., Chung, Sylvia A., Lalwani, Amit, Tsubota, Shoma, Beck, Dominik, Kadomatsu, Kenji, Beckers, Anneleen, Durink, Kaat, De Preter, Katleen, Speleman, Frank, Haber, Michelle, Norris, Murray D., Swarbrick, Alexander, Cheung, Belamy B., Marshall, Glenn M., Carter, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649872/
https://www.ncbi.nlm.nih.gov/pubmed/37958555
http://dx.doi.org/10.3390/ijms242115571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649872/
https://www.ncbi.nlm.nih.gov/pubmed/37958555
http://dx.doi.org/10.3390/ijms242115571

Ejemplares similares